Elisigen announced promising interim data from its Phase 1/2a study of NG101. The results demonstrated a 91% reduction in treatment burden for wet AMD patients, highlighting the potential for NG101 to significantly improve patient quality of life through long-term therapeutic efficacy.
Read Original Article (English)
*Note: This link will redirect you to the original source in English.